Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare

SANTA CLARA, Calif. - Oct. 28, 2025 - Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, today announced advancements in developing the company's robotics systems with physical artificial intelligence (AI) technologies that create simulated environments to accelerate future product innovation, optimize clinical workflows, and improve training for clinical teams.

Johnson & Johnson MedTech is using AI-driven simulation in development of the MONARCH™ Platform for Urology where virtual operating room environments can be created to assist clinical teams in setting up the robotic system before starting a procedure. Simulated patient anatomy and clinical scenarios can also be generated to model kidney stone procedures to help with learning and procedure planning. Leveraging NVIDIA Isaac for Healthcare, Johnson & Johnson MedTech can create high-fidelity digital twins using NVIDIA Omniverse libraries and build applications that simulate how the system may perform in the operating room and inside a patient. In addition, NVIDIA Cosmos world foundation models for synthetic data generation can help complete the picture with highly accurate, physics-based data.

"Simulation is the next frontier in surgical robotics," said Neda Cvijetic, Senior Vice President, Global Head of Robotics & Digital R&D, MedTech, Johnson & Johnson. "With AI-driven simulation, we can create high-fidelity digital twins that adhere to the laws of physics, such that the simulation accurately anticipates the real world and ultimately unlocks physical AI capabilities. As we launch new robotics technologies and continue accelerating our innovation pipeline, these simulations have the potential to enhance our differentiated technology development in support of our mission to deliver better patient outcomes."

Optimizing clinical settings and training for new robotic systems

Creating physics-based simulations of the entire robotic system including the tower, cart, fluid management system, and instruments is expected to provide research and development teams with the potential to test new features and model how the system might behave in real-world settings. The digital assets can also be used to support training and education efforts for clinical teams that adopt the MONARCH Platform for Urology.

"This is an exciting development in our use of AI to shape our robotics portfolio and position the MONARCH Platform for Urology for success," said Aleksandra Popovic, President, MONARCH, MedTech, Johnson & Johnson. "Our teams are convening the right technologies to capture value from data and shape new experiences with our systems before, during, and after surgery."

Pioneering robotics for bronchoscopy and urology
The MONARCH Platform is a first-to-market innovation in robotic-assisted bronchoscopy. The system uses robotic control with a novel endoluminal scope-in-sheath architecture that enables clinicians to locate and biopsy small nodules deep within the lung. The company recently introduced MONARCH QUEST with AI-enhanced navigation software for its bronchoscopy system, powered by the full-stack NVIDIA accelerated computing platform.

The MONARCH Platform for Urology is the latest innovation for robotic-assisted urologic procedures and will be commercially available in the U.S. in 2026. The system, ureteroscope, and endourology accessories are indicated to provide endoscopic visualization and access of organs, cavities and canals in the urinary tract with transurethral access or transurethral access in conjunction with percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract. Robotic assistance can allow surgeons to maintain precise instrument control during kidney stone procedures, providing the freedom to perform multiple tasks simultaneously by a single operator.

Learn more about the MONARCH Platform at https://www.jnjmedtech.com/en-US/product-family/monarch.

Instructions for Use and Important Safety Information
The MONARCH Bronchoscope and the MONARCH Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.

Complications from bronchoscopy may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. More serious complications from bronchoscopy may include collapsed lung, respiratory failure, hemorrhage, burns, heart attack or cardiac arrhythmia.

The MONARCH^TM Platform, Urology, the ureteroscope, and endourology accessories are indicated to provide endoscopic visualization and access of organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) with transurethral access or transurethral access in conjunction with percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.

Adverse effects from ureteroscopy may include pain, perforation of the ureter, urinoma, stricture of the ureter, avulsion of the ureter, urinary tract infection, urosepsis, bleeding, hydronephrosis, blood clots, residual stones, or injury of the ureter. Minor adverse effects following Mini-PCNL may include fever and nephrostomy leak. Major adverse effects related to access may include injuries to pleura, liver, spleen, colon, duodenum, and jejunum, and may result in bleeding, fever, pain, ileus, elevated counts, and gas or feces from the percutaneous nephrostomy (PCN) tube. Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, post percutaneous nephrolithotomy bleeding, arrhythmia, burns, inflammation, hypothermia, obstruction to the kidney, and injury to soft tissue. Adverse effects of these procedures may require prolonged surgical duration, additional surgical intervention, or conversion to other surgical techniques.

About Surgical Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit https://thenext.jnjmedtech.com.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to the MONARCH platform and the NVIDIA Demonstration Letter Agreement. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections ofJohnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges in new product development; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Media Contact:
Lindsey Diaz-MacInnis
[email protected]